CONTAK RENEWAL MODELS H125 AND H120 WITH THE MODEL 2865 VERSION 1.8 APPLICATION SOFTWARE
Guidant Corp. · Decision date Jan 26, 2004
What did the FDA approve?
FDA approved the CONTAK RENEWAL TR pulse generator on January 26, 2004. The approval statement lists an indication for patients with moderate to severe heart failure (NYHA Class III/IV), left ventricular dysfunction with EF <= 35%, QRS duration >= 120 ms, and symptoms persisting despite stable, optimal heart failure drug therapy as defined in the clinical trials section.
The device provides atrial-ventricular tracking modes to help preserve AV synchrony and adaptive-rate pacing for patients who would benefit from adjusted pacing rates concurrent with physical activity. The statement reports these device purposes but does not itself present independent proof of safety or clinical effectiveness. The record does not describe any supplement type or reason.
FDA approval order statement
APPROVAL FOR THE CONTAK RENEWAL TR. THE DEVICE IS INDICATED S FOLLOWS: THE CONTAK RENEWAL TR PULSE GENERATOR IS INDICATED FOR PATIENTS WHO HAVE MODERATE TO SEVERE HEART FAILURE (NYHA CLASS III/IV) INCLUDING LEFT VENTRICULAR DYSFUNCTION (EF <= 35%) AND QRS DURATION >= 120 MS AND REMAIN SYMPTOMATIC DESPITE STABLE, OPTIMAL HEART FAILURE DRUG THERAPY (AS DEFINED IN THE CLINICAL TRIALS SECTION). THE DEVICE PROVIDES ATRIAL-VENTRICULAR TRACKING MODES TO HELP PRESERVE AV SYNCHRONY, AND ADAPTIVE-RATE PACING FOR PATIENTS WHO WOULD BENEFIT FROM ADJUSTED PACING RATES CONCURRENT WITH PHYSICAL ACTIVITY.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 26, 2004
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P030005
- Regulatory pathway
- Premarket approval application
- Applicant
- Guidant Corp.
- Product code
- NKE
- Decision code
- APPR
- Decision date
- Jan 26, 2004
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P).
- Applicant
- Guidant Corp.
- Product code
- NKE
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P030005 received
Application receipt date recorded by FDA.
P030005 · FDA decision
APPR
P030005/S257 · Related supplement
VALITUDE (Model U125); VALITUDE X4 (Model U128); VISIONIST (Models U225, U226); VISIONIST X4 (Model U228)
Timeline entries are records held by MedtechLedger for P030005. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030005
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Guidant Corp. | PMA supplement | Oct 3, 2026 | FDA |
Explore the linked device profile
Other records with product code NKE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
BIOexpressP070008/S177 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 5, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Guidant Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4100 Hamline Ave. N, St Paul, MN, 55112
Sources and methodology
- Original FDA record: P030005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



